Kyverna Therapeutics
KYTX
90 hedge funds and large institutions have $762M invested in Kyverna Therapeutics in 2024 Q1 according to their latest regulatory filings, with 90 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
71.21% more ownership
Funds ownership: 0% → 71.21% (+71%)
99% less call options, than puts
Call options by funds: $5K | Put options by funds: $514K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVA
Vida Ventures Advisors
Boston,
Massachusetts
|
+$126M |
| 2 |
NV
Northpond Ventures
Bethesda,
Maryland
|
+$90.8M |
| 3 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$88.3M |
| 4 |
RI
RTW Investments
New York
|
+$51.7M |
| 5 |
DM
Deerfield Management
New York
|
+$40.8M |
Top Sellers
KYTX Hedge Fund Activity: Q1 2024 in Review
90 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Kyverna Therapeutics (KYTX) for Q1 2024, worth a combined $762M.
Buyers outnumbered sellers: 90 funds opened new KYTX positions and 0 closed out — a net gain of 90 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Vida Ventures Advisors, opening a new position worth an estimated $126M.
- 90 institutional investors held Kyverna Therapeutics (KYTX) as of Q1 2024, up from 0 in Q4 2023.
- Funds reported $762M of Kyverna Therapeutics stock for Q1 2024.
- 90 funds opened new Kyverna Therapeutics positions in Q1 2024 and 0 closed out, a net change of +90 holders.
- The largest Kyverna Therapeutics buyer in Q1 2024 was Vida Ventures Advisors, an estimated $126M added.
Based on aggregated 13F filings for Q1 2024.